Medical therapy cost considerations for glaucoma
- 1 July 2003
- journal article
- clinical trial
- Published by Elsevier BV in American Journal of Ophthalmology
- Vol. 136 (1), 18-25
- https://doi.org/10.1016/s0002-9394(03)00102-8
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- New Glaucoma Medications in the Geriatric Population: Efficacy and SafetyJournal of the American Geriatrics Society, 2002
- Twelve-Month Evaluation of Brimonidine-Purite Versus Brimonidine in Patients With Glaucoma or Ocular HypertensionJournal of Glaucoma, 2002
- Effects of common ophthalmic preservatives on ocular healthAdvances in Therapy, 2001
- A comparison of dorzolamide–timolol combination versus the concomitant drugsAmerican Journal of Ophthalmology, 2000
- Cost considerations of medical therapy for glaucomaAmerican Journal of Ophthalmology, 1999
- Medical Management of GlaucomaNew England Journal of Medicine, 1998
- Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertensionOphthalmology, 1998
- Cost of β-Adrenergic Receptor Blocking Agents for Ocular HypertensionAmerican Journal of Ophthalmology, 1992
- Comparison of Timolol Maleate and Levobunolol: Doses and Volume per BottleAmerican Journal of Ophthalmology, 1989
- Facilitating patient compliance in glaucoma therapySurvey of Ophthalmology, 1983